Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2005

View Archived Issues

Antiinflammatory properties of drugs acting on the renin-angiotensin system

New data on the survival benefits of Provenge in advanced prostate cancer

Low-dose doxepin therapy shows promise in primary sleep maintenance insomnia

MAZ-51 directly inhibits tumor growth in preclinical models

Discovery of a novel family of antimicrobial peptides

Update on the safety and antiviral effects of Actilon in hepatitis C

Phase I study of ADMVA HIV vaccine opens enrollment

BAL-8557 enters phase II for esophageal candidiasis

Abgenix to receive milestone payment from Chiron for oncology antibody

BioLineRx inlicenses three new preclinical compounds

deCODE submits IND for novel antiatherosclerosis compound DG-041

Roche's AmpliChip CYP450 Test receives FDA clearance

Positive results from field efficacy study of FluINsure

Phase III study of ferumoxytol as intravenous iron replacement therapy

Phase IIa trials of PT-141 in FSD and ED complete enrollment

Series A financing at Chelsea Therapeutics

BAY-43-9006 studied for pancreatic cancer in NCI-sponsored phase II study

Good safety profile found for GR-270773 in septic patients

Clinical trial confirms the benefits of conivaptan in the management of hyponatremia

Phase II data on the efficacy of PHP in distributive shock

First clinical data on the efficacy of peginterferon alfa-2b monotherapy in chronic hepatitis B

New data on ethacrynic acid

Corgentech files IND to begin phase I/II trial of NF-kappaB Decoy in eczema

Combinations of modafinil and an antidepressant agent claimed by Cephalon

Pfizer claims PDE5 inhibitors for use in hypertension and diabetes

AstraZeneca scientists describe new agents for the treatment of pain

Researchers at ACRAF present novel analgesic compounds

Agents for the treatment of proliferative disorders described in patent literature

New therapeutic candidates for the treatment of Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...